

Index

- acceptance and commitment therapy 114–115
- accommodation of OCD patient 173–174
- N*-acetyl aspartate 20
- N*-acetylcysteine 42
trichotillomania 212
- advocacy organizations 159–160
- age of onset of OCD 4
- akathisia, effect of haloperidol 50
- amiodarone, inhibition of cytochrome P450 35
- amisulpiride augmentation 52
- amygdala, and ERP 111
- amyotrophic lateral sclerosis, glutamatergic medications 42
- anankastic personality 9
- animal experiments, extinguishing of avoidance behavior 102
- anorexia nervosa, and body dysmorphic disorder 192
- anterior capsulotomy 22–23, 109
adverse effects 22–23
- anterior cingulate cortex
cingulotomy 23, 109
outcomes 22, 23
executive function, hoarding, compulsive 128
hyperactivity 21
- antiglutamatergic agents, SRI augmentation 55
- antipsychotic drugs
atypical (second-generation)
5-HT_{2A} receptor antagonism 55
and obsessive-compulsive symptoms 85
- augmentation therapy 49, 56
children 53–54
- drug-induced obsessive-compulsive symptoms 85–86
diagnosis 85–86
management 86
- hoarding symptoms 56
- low-dose vs high-dose 55
- and obsessive-compulsive symptoms 85
aripiprazole 53, 85
clozapine 83, 85
- management, future directions 86–87
olanzapine 85
quetiapine 85
risperidone 85
- treatment-resistant OCD in adults 95
- trichotillomania 211
- typical (first-generation) 49–50, 82
- anxiety disorders
generalized anxiety disorders 8, 64
- hoarding, compulsive 124, 125
- two-factor theory 102
- aripiprazole augmentation
5-HT_{1A} agonist 55
improvement in compulsion 56
pediatrics 54
SRI and second-generation antipsychotics 53, 85
- treatment-resistant OCD patients 52–53
- trichotillomania 211
- attention-deficit hyperactivity disorder 126
- augmentation therapy *see* SRI augmentation
- autogenous obsessions 107
- aversion, verbal representations 103
- avoidance behavior
animal experiments 102
classical conditioning 102
two-factor theory 102
- benztropine, akathisia effects 50
- bipolar disorder *see* major depressive disorders; mood disorders
- bizarreness 13–15
- body dysmorphic disorder 191–202
case study 192
clinical features 192, 194
in adolescence 194–195
anxiety disorders 194
functioning and quality of life 194
gender ratio 192
suicidal ideation 194
suicide completed 194
- comorbidity 193
major depressive disorder 193
- OCD combined with body dysmorphic disorder 193
- substance use disorders 193
- trichotillomania 192, 207
- defined 191
- diagnosis 200–202
questions to ask patients (*table*) 201
- functioning and quality of life 194
- future trends 202
- history 191
somatoform disorder 191
- major depressive disorders, prevalence of body dysmorphic disorder 192
- preoccupation with perceived defects 192
compulsive behaviors 193
delusions of reference 193
poor insight 193
skin picking 193
tanning 193
- prevalence 191–192
anorexia nervosa 192
social phobia 192
trichotillomania 192
- relationship to OCD 198–200
- schizophrenia with obsessive-compulsive symptoms 77–78
- suicidal ideation 194
- suicide completed 194
- treatment 195
CBT 108, 197–198
core elements 198
frequency and duration 198
habit reversal, skin picking 198
discouraging surgery 195–196
ERP 197
pharmacotherapy 196–197
psychoeducation 195
SSRIs 196–197
high SRI doses 197
strategies 197
- Brown Assessment of Beliefs Scale (BABS) 75
- bupirone, SRI augmentation 54
- capsulotomy 22–23
adverse effects 22–23

- gamma ventral capsulotomy 22
 thermocapsulotomy 22
 caudate nucleus
 and ERP 103–104
 hyperactivity 21
 charitable organizations 159–160
 childhood and adolescence OCD
 92–95, 138–150
 acute-onset subtype 93
 following PANDAS 93
 CBT *see* cognitive-behavioral
 therapy, pediatric OCD
 clinical description/ assessment
 92–93
 clinical pearls 98
 cognitive-behavioral
 conceptualization of OCD
 139–140
 neutralizing behavior 139–140
 pediatric bipolar disorder (BD) 96
 comorbid conditions 92–93
 developmental challenges 140–141
 diagnosis 140, 141
 clinical interviews 141
 clinician ratings 142
 self-report and parent ratings
 141–142
 epidemiology
 age of onset 92, 138
 prevalence 92
 management
 augmentation strategy 96
 comorbid disorders 96–97
 initiation and maintenance of
 treatment 97
 meta-analysis 95
 new directions 96
 parental attitudes associated with
 OCD (*table*) 174
 pathophysiological model 93–94
 dopamine 94
 glutamate 94
 pediatric Y-BOCS (CYBOCS) 53
 pharmacological management 97
 antipsychotics 95
 D-cycloserine 95–96
 FDA approval 95
 non-response to SRIs 49
 riluzole 96
 side effects 97
 SRIs 94
 clomipramine 94, 95
 SSRIs 94–97
 dosages of SRIs, SSRIs (*table*) 95
 interactions with treatments
 for ADHD, and bipolar
 disorder 96
 suicide and SSRIs 97
 structural neuroimaging 20
 symptom dimensions 93
 tic disorders and dopaminergic
 dysfunction 94
 untreated 138
 see also family in OCD treatment
 Children of Hoarders (COH) 162
 cimetidine, inhibition of cytochrome
 P450 35, 36
 ciprofloxacin 35
 citalopram 34, 85
 dosing guidelines 36
 pediatric dosages 95
 classical conditioning, development of
 OCD 102
 classification of OCD
 as anxiety disorder, DSM-IV 1, 5
 association with comorbid disorders
 (*table*) 6
 factors 6
 symptoms 5–6
 clomipramine
 augmentation agent in SSRI therapy
 31–32
 dosage guidelines
 optimal doses 31
 pediatric dosages 94
 dosage guidelines (*table*) 36, 55
 fluvoxamine/fluoxetine effects 32
 history of clinical use 30, 31–32
 intravenous form 32
 schizophrenia with obsessive-
 compulsive symptoms 82
 and severe depression 65
 side effects 31
 tolerability 31
 trichotillomania 211
 vs ERP 106
 vs fluvoxamine 106
 with/without ERP 105–106
 see also SRIs
 clozapine, treatment-resistant OCD 53
 Clutterers Anonymous (CLA) 155
 cognitive models of OCD 1
 cognitive-behavioral therapy 64
 added to ERP 66
 and D-cycloserine 96
 family therapy 115
 strategies 64
 thought stopping 104–105
 vs ERP 104–105, 114
 see also exposure and response
 prevention therapy
 cognitive-behavioral therapy, pediatric
 OCD 96, 138–150
 collaboration between parent, child
 and therapist 144
 conceptualization of OCD, behavior,
 avoidance or escape from the
 fear 139–140
 developmental challenges
 anxiety disorders 140
 behavioral disorders 140
 CBT protocols 140–141
 depressive disorders 140
 family context 140
 tic disorders 140
 effective persuasion 144
 ERP 138–139, 145
 gradual exposure 145
 fear temperature 145
 frequent practice 146
 future directions 149–150
 Phase I: biopsychosocial assessment/
 treatment 141–142, 147–148
 Phase II: building treatment
 readiness 142–144, 148
 Phase III: RIDE up and down the
 Worry Hill 144–146,
 148–149
 Phase IV: after the RIDE 146–147,
 149
 RALLY, parents' role 144, 146
 rewards 146
 RIDE acronym 144–146, 148–149
 slips and relapses 146–147
 symptom analysis 142
 treatment completion and booster
 sessions 147
 Worry Hill 141–150
 community support 152–170
 adults in workplace 165
 charitable and advocacy
 organizations 159–160
 family-to-family class 158–159
 media 165–169
 commercial advertizing 168–169
 entertainment media 166–168
 literature 168
 news 168
 school environment 162–165
 social and economic costs 152
 support groups 152–165
 additional groups offering help
 162
 GOAL 155
 online 156
 peer-led 154
 professionally assisted 153–154
 pros and cons 156–157
 starting 157–158
 twelve-step 154–155
 compulsions
 content of primary compulsion
 (*table*) 3
 required diagnostic criteria (*table*) 2
 table 3
 compulsive rituals *see* rituals
 COMT 54

Index

- COMT Val158Met polymorphism 127
- contamination fear 111
ERP 111
- cortico-striato-thalamo-cortical circuitry 20, 111
ERP 20, 111
OCD vs healthy volunteers 21
- course of OCD 10–11
untreated 49
- cytochrome P450 system inhibitors 35–36
specific enzymes (*table*) 35
- D-cycloserine 42, 53
with cognitive-behavioral therapy 96
and ERP 106
- deep brain stimulation 24–25, 109
- delusions of reference, body dysmorphic disorder 193
- delusions vs obsessions 12–16
- depression 7
bipolar disorder 8, 63–64
cognitive therapy 66
and presentation of OCD 62
see also major depressive disorder; mood disorders
- desmethylclomipramine 32, 36
- diagnosis of OCD 2, 3
antipsychotic drug-induced symptoms 85–86
in clinical setting 12
compulsions 2
diagnostic criteria 9
misdiagnosis 2, 12, 16
obsessions 2
- diagnosis of obsessive-compulsive personality disorder
criteria 9
diagnostic criteria 9
- dialectical behavior therapy 115
- differential diagnosis of OCD 1
obsessions and delusions 13
- disgust reaction 5
with/without anxiety, ERP 111–113
- dopamine, pathophysiological model of OCD 94
- dronabinol, treatment-resistant OCD 53
- drug-induced obsessive-compulsive symptoms 85–86
diagnosis 85–86
management 86
- DSM-IV criteria 1, 5
- eating disorders 8
schizophrenia with obsessive-compulsive symptoms 77–78
- education
psychoeducation 179
- school environment 162–165
- ego-dystonic thought vs ego-syntonic thought 13, 16, 75
- Epidemiological Catchment Area study 3
- epidemiology of OCD 3–5
age of onset 4
case example 4
childhood and adolescence 92
- Epidemiological Catchment Area study 3
late-onset OCD 4
schizophrenia with obsessive-compulsive symptoms 71–74
rate 72–74
- ERP *see* exposure and response prevention therapy
- erythromycin 35
inhibition of cytochrome P450 35
- escitalopram 34
dosing guidelines 36
pediatric dosages 36, 95
- exposure and response prevention (ERP) 14, 30, 64, 102–115, 184–190
adjunctive therapies 103, 114–115
acceptance and commitment therapy 114–115
cognitive-behavioral family therapy 115
cognitive therapy 114
dialectical behavior therapy 115
personality disordered patients with suicidal ideation 115
- animal experiments 102
- body dysmorphic disorder 197
- CBT techniques 104–105
thought stopping 104–105
- childhood and adolescence OCD 138–139, 145
- complications to efficacy 110
comorbidity 111
depression 110–111
overvalued ideation 110
personality 111
- contamination fear 111
disgust reaction with/without anxiety 111–113
disgust sensitivity as major etiological factor in OCD 111
early ERP studies 104
- efficacy for severe depressive symptoms 64–65
- expert consensus guidelines 185
- family involvement 179
as first-line treatment 185
- hospitalization 185
- in vivo and imaginal exposure 102–103
- intensive outpatient therapy 184–185
- intensive programs 186–187, 188–190
case examples 187–188
rituals 186
vs weekly ERP 107
- intensive residential treatment 185
development in severe OCD 185–186
frequency of treatment 185
levels of treatment 184
long-term effects 106–107
- models
autogenous obsessions 107
five-factor model of personality 110, 111
reactive obsessions 107
theoretical model 102–103, 115
- motivational interviewing 105
- neurology
amygdala 111
caudate nucleus 103–104
cortico-striatal-thalamic-cortical circuitry 20, 111
- neurosurgical OCD options 109
anterior capsulotomy 109
anterior cingulotomy 109
deep brain stimulation 109
limbic leucotomy 24, 109
subcaudate tractotomy 109
transcranial magnetic stimulation 109
- OCD with obsessive-compulsive spectrum disorders 108
anxiety disorders, two-factor theory 102
body dysmorphic disorder 108
hypochondriasis 108
Tourette's syndrome 108–109
trichotillomania 108–109
- OCD subtypes and efficacy of ERP 107–108
- pediatric OCD, gradual exposure 145
- programs, in vivo and imaginal exposure 102–103
- relational frame theory 103–104, 114–115
acceptance and commitment theory 103
functional contextualism 103
language and impact on human emotions 103
- serotonergic activity changes 103
- treatment for OCD 104
planning 113–114
resistant vs refractory 109
with SRIs vs stress management training 105
with SSRI augmentation 106

- therapy/therapist/patient variables 113
 vs anxiety management 105
 vs cognitive therapy 105
 studies 102–103, 105
 vs medications 105–106
 clomipramine 105–106
 D-cycloserine 106
 fluoxetine and behavioral therapy 103
 fluvoxamine 104
see also cognitive-behavioral therapy
- family in OCD treatment 172–180
 accommodation 173–174
 antagonism 174–175
 assessment instruments 178
 cognitive style of family 175
 family interactions 179–180
 active involvement in ERP 180
 change patient's behavior 179
 relaxation training 180
 involvement in treatment 176–177
 adults 177–178
 children and adolescents 176–177
 outcome 175–176
 overprotection 175
 parental attitudes associated with OCD 174
 predictors of treatment non-response 175
 psychoeducation 179
 ERP 179
 fear thermometer vs Subjective Units of Distress scale 179
 quality of life 172–173
 stigma 172–173
 role of family 173
 summary 178
 assessment 178
 guidelines 178–179, 180
 support for family members 178–179
 treatment non-response, associated factors 175
see also childhood and adolescence OCD
- family-to-family class, community support 158–159
- FEAR, and acceptance and commitment therapy 114
- fear and avoidance behavior, two-factor theory 102
- fear thermometer, vs Subjective Units of Distress Scale, psychoeducation 179
- fluoxetine 33
 and behavioral therapy 103
 with clomipramine 32
 dosing guidelines 36
- half-life 33
 pediatric dosages 95
- fluvoxamine 21, 32–33
 and antipsychotics 50
 with clomipramine 32
 controlled release formulation 33
 half-life 33
 pediatric dosages 95
 vs ERP 106
- gamblers 126
 Iowa gambling task 128
- gamma ventral capsulotomy 22
- group A beta-hemolytic streptococcal infection 7
- gender distribution 5
- generalized anxiety disorder 8, 64
 two-factor theory 102
- genetic and autoimmune causative factors 6–7
- glutamate
 levels in cerebrospinal fluid 55
 pathophysiological model of OCD 94
- glutamatergic medications 42–43
 D-cycloserine (DCS) 42
 memantine 42
 N-acetylcysteine 42
 riluzole 42
 trichotillomania 212
- grapefruit, inhibition of cytochrome P450 35
- GRIN2B (gene for NMDA glutamatergic receptor) 94
- habit reversal therapy 209–210
- haloperidol
 adverse effects, akathisia 50
 effects on mood and anxiety 56
 SRI augmentation 50
 trichotillomania 211
 vs placebo 50
- hoarding, compulsive 61, 122–133
 and anxiety disorders 124, 125
 course and features 123
 demographic features 123–124
 emotional attachment to possessions 129
 onset and course 123
 prevalence 122, 123, 125
 subtype of OCD 125
 definition 122–123
 diagnostic placement 125–126
 with attention-deficit hyperactivity disorder 126
 axis I comorbidity 124–125
 biopsychosocial model 127–131
 impulse control disorders 125–126
- familial and environmental vulnerabilities 126, 127
 fire hazard 126
 relationships 126–127
 social and economic burden 126–127
 stressful life events 127
 work environment 126
- maladaptive behavioral patterns 129–131
 behavioral avoidance 129–130
 behavioral disinhibition 130
 insight and hoarding 130
 poor problem recognition and motivation 130–131
- maladaptive cognitive content/process 128–129
 attention 128
 attentional capacity 128
 beliefs about possessions 129
 executive function 128–129
 perfectionistic beliefs 129
- memory 128
 left parahippocampal gyrus 128
 spatial vs categorical recall 128
- neurology
 anterior cingulate cortex 128
 orbitofrontal cortex 129
 prefrontal cortex 129
 and OCD 125
- psychiatric and medical comorbidities 124–125
 anxiety disorders 124
 obsessive-compulsive personality disorder 124
 personality disorders 124
 skin picking 126
 trichotillomania 108–109, 126
- symptoms 6
 antipsychotics 56
 treatment 131–132
 behavioral treatment 131
 CBT 131–132, 133
 ERP 109
 pharmacological treatment 131
- hospitalization, ERP 185
 5-HT_{1A} autoreceptor 54
 5-HT_{2A} autoreceptor 55
 antagonism, atypical (second-generation) antipsychotics 55
 clozapine blocking 55
- hypochondriasis 108
- hypomania 63
- imipramine, prior to ERP 65
- impulse control disorder 207
- impulse control disorders 125–126, 207
- insight, body dysmorphic disorder 193
- insight into OCD 3, 11
- International OCD Foundation 160–161

Index

- language
 cognition 103
 cognitive fusion 103
 impact on human emotions,
 relational frame theory 103
 radical behaviorism 103
 late-onset OCD 4
 Leyton Obsessional Inventory-Child
 Version 142
 limbic leucotomy, outcomes 23, 24
 lobotomy 21
- major depressive disorder 7–8, 61–63,
 61–66
 with body dysmorphic disorder 193
 defined 61
 ERP with SSRIs 30–31
 prevalence of body dysmorphic
 disorder 192
 in samples of adult OCD patients 62
 schizophrenia with obsessive-
 compulsive symptoms
 77–78
see also mood disorders
- media 165–169
 commercial advertising 168–169
 entertainment media 166–168
 literature 168
 news 168
- memantine 42
 treatment-resistant OCD patients
 53
- mirtazapine augmentation 31
 misdiagnosis of OCD 2, 12, 16
 slowness 12
- monoamine oxidase inhibitors 43
 phenelzine 43
- mood disorders 61–69
 case example 66–69
 ERP 67
 religious obsessions 66
 sexual obsessions and mental
 rituals 66
 comorbid 61–69
 depression 7
 cognitive therapy 66
 and presentation of OCD 62
 disease comorbidity 65
 medication 65–66
 pediatric OCD 96
 unipolar and bipolar 61–66
 motivational interviewing 105
 MRI, diffusion tensor 20
 Multidimensional Anxiety Scale 142
- N*-acetyl aspartate 20
N-acetylcysteine 42
 trichotillomania 212
 naltrexone 212
- National Alliance on Mental Illness 159
 neurobiology of OCD 20–21
 neuroimaging
 functional 21
 cortico-striatal-thalamic-cortical
 circuitry in OCD 21
 structural 20–21
 pediatric OCD patients 20
- obsessions 61
 autogenous vs reactive 107
 content of primary obsession 2
 images 2
 required diagnostic criteria 2
 vs compulsions 56
 vs delusions 12–16
 obsessive-compulsive disorder (OCD)
 combined with body dysmorphic
 disorder 193
 development of OCD 102
 disgust sensitivity as major
 etiologial factor 111
 neurosurgical OCD options 109
 obsessive-compulsive personality
 disorder 9–10
 age of onset (vs OCD) 4
 diagnostic criteria 9
 driving force 10
 and hoarding 124
 vs OCD 9–10
- OCD, *see* obsessive-compulsive
 disorder
- OCD Center Manitoba 161
 OCD Ireland 161
 OCD-UK 161–162
- olanzapine
 schizophrenia with obsessive-
 compulsive symptoms 84
 trichotillomania 211
 olanzapine augmentation 51
 maximal dose 55
 treatment-resistant OCD 51
- ondansetron 53
 Ontario OCD Network 161
- orbitofrontal cortex
 hoarding, compulsive 129
 hyperactivity 21
- overprotection of OCD patient 175
 overvalued ideation 11
- PANDAS (pediatric autoimmune
 neuropsychiatric disorders
 associated with streptococcal
 infections) 7
 acute-onset subtype of pediatric
 OCD 93
- paranoia 16
 parental attitudes 174
 see also family in OCD treatment
- paroxetine 33, 35
 dosing guidelines 33, 35, 36
 half-life 33
 long-term effectiveness 33
 pediatric dosages 95
 pediatric OCD *see* childhood and
 adolescence OCD
 Pediatric OCD Treatment Study
 (POTS) 95
- personality
 five-factor model 110, 111
 see also obsessive-compulsive
 personality disorder
- phenelzine 43
 pimozide
 augmentation 50
 trichotillomania 211
- postpartum depression 11
 and OCD 63
 postpartum obsessions 2
 post-traumatic stress disorder 114
 predictors of treatment non-response 175
 prefrontal cortex, hoarding,
 compulsive 129
- pregnancy 11
- psychiatric disorders 7–9
 comorbidity in OCD 6, 7–9
 see also mood disorders
- psychoeducation 179
 psychological treatment 64
 effects of comorbidity 64–65
 psychopathology, axis I and II 61
 psychostimulants, trichotillomania 211
- quality of life, family in OCD treatment
 172–173
- quetiapine
 augmentation 52, 56
 schizophrenia with obsessive-
 compulsive symptoms 84
- reactive obsessions 107
 relational frame theory 103–104, 114–115
 acceptance and commitment theory
 103
 cognitive fusion 103
 functional contextualism 103
 language and impact on human
 emotions 103
 relaxation training 180
 religious obsessions 62, 66
- riluzole
 augmentation 42, 53, 54, 55
 pediatrics 96
 trichotillomania 212
- risperidone
 schizophrenia with obsessive-
 compulsive symptoms 84
 trichotillomania 211

- risperidone augmentation 50–51, 56
 dose-dependent response rate 55
 low-dose 51
 obsessions vs compulsions 56
 pediatrics 53
 responders, in fluvoxamine-resistant
 group 51
 vs haloperidol 50
- rituals 66, 173, 186
 ERP 186
- schizophrenia 8
 chronic, rate of obsessive-
 compulsive symptoms 73
 clozapine-treated, de novo obsessive-
 compulsive symptoms 85
 misdiagnosis 14–15
 recent-onset
 olanzapine 85
 rate of obsessive-compulsive
 symptoms 73
 risperidone 85
- schizophrenia with obsessive-
 compulsive symptoms 71
 adolescent, rate of obsessive-
 compulsive symptoms 74
 alternative underlying mechanisms
 83–84
 atypical (second-generation)
 antipsychotics 82–83
 body dysmorphic disorder 77–78
 Brown Assessment of Beliefs Scale 75
 case reports 76–76, 79–80
 childhood-onset and adolescent
 schizophrenia 78–79, 80
 clinical characteristics 71–74
 comparative characteristics 72
 course 77
 eating disorders 77–78
 effect on schizophrenia symptom
 severity 76–77
 ego-dystonic 75
 ego-syntonic 75
 elderly 80
 rate of obsessive-compulsive
 symptoms 74
 epidemiology 71–74
 rate 72–74
 hallucinations 75
 independent of schizophrenia
 symptoms 76
 insight 74
 major depressive disorder 77–78
 obsessive thoughts 74
 OCD characterized 74–75
 overlap with OCD 71
 overlapping with positive
 schizophrenia symptoms 76
 phenomenology, schizophrenia 71
- psychopathological phenotypes 75
 recent-onset, rate of obsessive-
 compulsive symptoms 73
 schizotypal personality disorder 56,
 80–82
 thought insertion 74
 tic disorders 77–78
 treatment 85
 addition of SSRI to atypical
 (second-generation)
 antipsychotics 84–85
 aripiprazole 84
 clozapine 85
 electroconvulsive therapy 85
 lamotrigine 84
 memantine 83
 monotherapy with atypical
 (second-generation)
 antipsychotics 84, 85
 olanzapine 84
 quetiapine 84
 recommendations 84–85
 riluzole 83
 risperidone 83, 84
 prepulse inhibition 83
 SRIs 82
 antipsychotic drug
 combination 82
 clomipramine 82
 fluvoxamine 82
 ziprasidone 84
 treatment of schizophrenia with
 obsessive-compulsive
 symptoms 82–85
 typical (first-generation)
 antipsychotics 82
 Y-BOCS 75
- schizotypal personality disorder 56,
 80–82
 rate of obsessive-compulsive
 symptoms 81
- school environment 162–165
- selective serotonin reuptake inhibitors
 (SSRIs) 30–43, 94–97
 with amiodarone, ciprofloxacin,
 erythromycin, grapefruit 35
 choice 35
 clomipramine as augmentation
 agent 31–32
 comparison trials 31
 cytochrome P450 system inhibitors
 35–36
 dosing guidelines 36–38
 citalopram 36
 escitalopram 36
 fluoxetine 36
 fluvoxamine 36
 milligram equivalency 37
 paroxetine 36
- sertraline 36
 two SSRIs 38
 maintenance of treatment 41
 pediatric, interactions with
 treatments for attention-
 deficit hyperactivity disorder,
 and bipolar disorder 96
 rapid titration protocol 37–38
 side effects 35, 38–41
 agitation 38
 apathy 41
 discontinuation syndrome 40
 excessive sweating 39
 gastrointestinal 38
 bleeding 40
 hyponatremia 39
 movement disorders 39
 other 41
 risk during pregnancy 40
 serotonin syndrome 39
 sexual 40
 bupropion 41
 busipirone 41
 sildenafil 41
 tachyphylaxis 39
 weight gain 41
 switching antidepressants 37–38
- serotonin hypothesis of OCD 93–94
 serotonin norepinephrine reuptake
 inhibitors (SNRIs) 34
 serotonin receptor, subtypes 54
 serotonin reuptake inhibitors (SRIs) 95
 augmentation 49–56
 pharmacological mechanism
 54–56
 time to response 55
 treatment-resistant OCD 49
 dosage guidelines, clomipramine
 36 55
 dosage guidelines 36, 55
 non-response to SRIs 49
 treatment for depression and OCD
 65–66
- serotonin transporter 54
 sertraline 33–34, 35, 85
 dosing guidelines 34, 36
 high dose 34
 longer-term outcomes 33
 pediatric dosages 95
 side effects 34
 sexual obsessions 62
 skin picking
 body dysmorphic disorder 193
 reversal (CBT) 198
 social anxiety disorder 64
 social and economic burden,
 compulsive hoarding, work
 environment 126
 social and economic costs of OCD 152

Index

- social phobia, and body dysmorphic disorder 192
- SRI *see* serotonin reuptake inhibitors
- SSRIs *see* selective serotonin reuptake inhibitors
- body dysmorphic disorder 196–197
- high SRI doses, body dysmorphic disorder 197
- trichotillomania 210–211
- stereotactic ablation 21–25
- stigma of OCD patient 172–173
- streptococcal infections 7
- acute-onset subtype of pediatric OCD 93
- see also* PANDAS
- stress, hoarding, compulsive, life events 127
- subcaudate tractotomy 23–24, 109
- outcomes 23, 24
- Subjective Units of Distress scale (SUDS) 179
- substance use disorders and body dysmorphic disorder 193
- suicidal ideation 115
- body dysmorphic disorder 194
- and SSRIs 97
- suicide, completed, body dysmorphic disorder 194
- support groups 152–165
- surgical techniques 21–25
- anterior capsulotomy 22–23
- anterior cingulotomy 23
- capsulotomy 22–23
- gamma ventral capsulotomy 22
- history 21
- history of surgery for OCD 21
- limbic leucotomy 24, 109
- lobotomy 21
- outcomes 22
- stereotactic ablation 21–25
- subcaudate tractotomy 23–24, 109
- Sydenham's chorea 7
- symptom dimensions 5–6, 93
- tanning, body dysmorphic disorder 193
- thermocapsulotomy 22
- adverse effects 22–23
- thought insertion 1, 16
- thought stopping 104–105
- thought withdrawal 16
- tic disorders 6, 8, 56
- family history 4
- linked to dopaminergic dysfunction 94
- topiramate, trichotillomania 212
- Tourette's syndrome 6, 8, 53, 108–109, 207
- ERP 108–109
- transcranial magnetic stimulation 109
- transformation obsessions 13, 14
- treatment of OCD
- community support 152–170
- family involvement 172–180
- non-response 175
- see also* cognitive-behavioral therapy; exposure and response prevention therapy; *named medications*
- trichobezoars 209
- trichotillomania 108–109, 126, 207–213
- assessment 209
- automatic vs focused hairpulling 209
- rating scales 209
- behavioral treatments and ERP 108–109, 209–210
- comorbid conditions 209
- body dysmorphic disorder 192, 207
- compulsive skin picking 207–208
- eating disorders 207
- hypochondriasis 207
- neuropsychological deficits 208
- obsessive-compulsive spectrum disorders 207
- tic disorders 212
- Tourette's syndrome 207
- diagnostic criteria 207, 212
- emerging treatments 211–212
- epidemiology and natural history 207–208
- genetics 208
- habit reversal therapy 209–210
- neuroimaging 208–209
- pharmacological treatments 210
- antipsychotics 211
- aripiprazole 211
- clomipramine 211
- glutamate-modulating compounds 212
- haloperidol 211
- N*-acetylcysteine 212
- naltrexone 212
- olanzapine 211
- pimozide 211
- psychostimulants 211
- riluzole 212
- risperidone 211
- SSRIs 210–211
- topiramate 212
- support groups 212
- Trichotillomania Learning Center 162
- tricyclic antidepressants *see* clomipramine
- twins, incidence of OCD 6
- venlafaxine 34–35
- work environment
- community support 165
- hoarding, compulsive 126
- Worry Hill approach 141–150
- child's role 144, 145
- RALLY, parents' role 146
- RIDE acronym 144–146, 148–149
- Yale–Brown Obsessive-Compulsive Scale (Y-BOCS) scores
- pediatric version (CY-BOCS), childhood and adolescence OCD 53, 93
- SRI augmentation 50, 51, 52, 53
- Y-BOCS, *see* Yale–Brown Obsessive-Compulsive Scale
- ziprasidone
- schizophrenia with obsessive-compulsive symptoms 84
- treatment-resistant OCD 53